Implantable devices for management of chronic heart failure: defibrillators and biventricular pacing therapy

Luis A Pires1

  • 1Department of Medicine, St John Hospital and Medical Center, and Wayne State University School of Medicine, Detroit, Michigan 48236, USA. luis.pires@stjohn.org

Insights

Device therapy, including implantable cardioverter-defibrillators and cardiac resynchronization therapy, offers significant benefits for managing chronic heart failure patients, improving survival and quality of life.

Area of Science:

  • Cardiology
  • Medical Devices

Background:

  • Chronic heart failure (CHF) is a growing epidemic with high morbidity and mortality.
  • Pharmacologic therapy improves survival but does not fully address CHF challenges.

Purpose of the Study:

  • To review recent advancements in non-pharmacologic, device-based treatments for chronic heart failure.
  • To highlight the role of implantable cardioverter-defibrillators and cardiac resynchronization therapy in CHF management.

Main Methods:

  • Review of recent clinical trials and data on device-based therapies for CHF.
  • Analysis of outcomes for implantable cardioverter-defibrillator (ICD) and biventricular pacing (cardiac resynchronization therapy - CRT).

Main Results:

  • ICD therapy significantly reduces mortality in mild to moderate heart failure by preventing sudden arrhythmic death.
  • CRT improves symptoms, quality of life, exercise tolerance, and left ventricular function in advanced heart failure patients with specific criteria (LVEF ≤ 35%, QRS > 120 ms).
  • Approximately 30% of patients do not respond to CRT; ongoing studies aim to identify responders and explore CRT in patients with normal QRS duration.

Conclusions:

  • Device therapy (ICD and CRT) is an integral, adjunctive component of chronic heart failure management alongside optimal medical therapy.
  • The choice of device depends on individual patient characteristics and clinical presentation.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...